CJC‐1295 (No DAC) Growth Hormone Axis Research Peptide

CJC‐1295 without DAC (also known as Mod GRF 1‐29) is a high-purity, research-grade synthetic analog of growth hormone–releasing hormone (GHRH) engineered for enhanced stability and receptor affinity while maintaining a relatively short half‐life. Unlike its DAC‐conjugated counterpart, this variant supports more physiologic, pulsatile GH release patterns in preclinical models, enabling precise temporal control of GH axis activation.

Molecular Mechanistic Profile

• Mechanistically, CJC‐1295 (no DAC):

  Binds to GHRH receptors on anterior pituitary somatotrophs, enhancing endogenous growth hormone (GH) release and downstream insulin‐like growth factor‐1 (IGF‐1) signaling.

• Exhibits a short plasma half‐life on the order of ~30 minutes to 1–2 hours, producing discrete GH pulses that more closely mimic physiologic circadian secretion than the prolonged plateau seen with DAC‐modified forms.

• Is frequently combined with GH secretagogues such as Ipamorelin or GHRP‐2 in blends to study synergistic stimulation of the GH axis via dual receptor pathways.

These characteristics make the no‐DAC variant well suited for experiments focused on pulsatile GH dynamics, feedback behavior, and acute signaling events.

Integrated Research Applications

CJC‐1295 (no DAC) is used across several GH/IGF‐1–related research domains:

• GH pulsatility and endocrine modeling: Time‐course studies of GH and IGF‐1 secretion, receptor sensitivity, and feedback regulation under short‐acting GHRH analog stimulation.

• Body‐composition and metabolism models: Preclinical work on muscle protein synthesis, lipolysis, carbohydrate metabolism, and recovery from catabolic states, often in combination with other GH secretagogues.

• Comparative pharmacology: Side‐by‐side evaluation of CJC‐1295 with and without DAC to delineate how half‐life extension and albumin binding alter GH exposure profiles and downstream outcomes.

  Because the no‐DAC form clears relatively quickly, it is favored where investigators want discrete GH spikes and troughs rather than continuous receptor engagement.

Analytical Validation, Formulation, and Storage

• Vendors supply CJC‐1295 (no DAC) as lyophilized peptide, commonly in 2–5 mg vials, with specifications such as:

• Purity: ≥98–99%

• Identity: Confirmed by mass spectrometry and sequence analysis matching the C152H252N44O42 profile and 29–amino acid GHRH analog sequence.

• Form: White lyophilized powder requiring reconstitution with sterile bacteriostatic

  water or other suitable solvent prior to research use. Storage guidance (aligned with your format):

• Store in a cool, dry place away from light while lyophilized.

• After constitution, refrigerate the solution; for longer‐term storage, freezing at approximately −20 °C is recommended to maintain peptide integrity.

NextGenPeps offers CJC No DAC strictly as a laboratory research peptide for use in controlled experimental settings. It is not approved as a pharmaceutical product and is not intended for human use, self-administration, or clinical research involving human subjects.